In this article, we will list the 5 Worst Blue Chip Stocks to Buy Now. Please visit 8 Worst Blue Chip Stocks to Buy Now if you would like to see the extended list and the methodology behind it.
5. Intuitive Surgical, Inc. (NASDAQ:ISRG)
On July 9, 2026, BMO Capital analyst Vik Chopra initiated coverage of Intuitive Surgical, Inc. (NASDAQ:ISRG) with an Outperform rating and $518 price target. Chopra said the da Vinci 5 upgrade cycle remains in the early innings, procedure growth is broadening into new specialties and geographies, and the earnings stream is “durable and visible.”
On July 6, Evercore ISI lowered the firm’s price target on Intuitive Surgical to $430 from $480 and kept an In Line rating on the shares. Evercore ISI said its Q2 preview for MedTech, Life Sciences Tools, and Diagnostics highlights generally healthy procedure volumes and capital expenditure trends across the sector.
Last month, BofA analyst Travis Steed lowered the firm’s price target on Intuitive Surgical to $515 from $520 and kept a Buy rating on the shares. Steed noted that BofA’s services team continues to highlight a lower utilization environment and took a more conservative view on 2027 medtech company estimates, given that valuations already reflect utilization risk. Steed also assumed inflation will be more of a headwind in 2027, with less margin expansion for medtech, and lowered 2027 estimates across the firm’s larger-cap coverage with exposure to utilization and inflation.
Intuitive Surgical, Inc. (NASDAQ:ISRG) develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.
4. Pfizer Inc. (NYSE:PFE)
On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer, regardless of cisplatin eligibility. Pfizer said this marks the first platinum-free regimen approved for adult patients with MIBC, regardless of cisplatin eligibility.
The approval was based on results from the pivotal Phase 3 EV-304 clinical trial, which were presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium. The expanded indication builds on the November 2025 U.S. FDA approval of the combination for use as neoadjuvant and adjuvant treatment in cisplatin-ineligible adult patients with MIBC, based on results from the EV-303 Phase 3 clinical trial published in the New England Journal of Medicine.
Also on July 10, BofA lowered the firm’s price target on Pfizer to $26 from $27 and kept a Neutral rating on the shares. On July 6, HSBC downgraded Pfizer to Hold from Buy with a price target of $28, down from $32. HSBC lowered its view of the probability to market of sigvotatug vedotin to 40% following the Phase 3 setback in NSCLC and said it is now “less convinced” regarding short-term re-rating potential due to recent executive management changes and “a paucity of short-term re-rating catalysts.”
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
3. EQT Corporation (NYSE:EQT)
On July 8, 2026, UBS lowered the firm’s price target on EQT Corporation (NYSE:EQT) to $73 from $74 previously and kept a Buy rating on the shares.
On July 2, Jefferies analyst Lloyd Byrne lowered the firm’s price target on EQT Corporation (NYSE:EQT) to $75 from $77 and kept a Buy rating on the shares as part of a Q2 preview. Byrne said Jefferies expects EQT to post Q2 EBITDA of $1.13B, just below the consensus of $1.19B.
On June 30, Freedom Broker initiated coverage of EQT Corporation (NYSE:EQT) with a Buy rating and $79 price target on the shares. The firm said EQT is the largest U.S. natural gas producer and is positioned to benefit from improving natural gas market fundamentals.
EQT Corporation (NYSE:EQT) engages in the exploration, production, gathering, and transmission of hydrocarbons and natural gas.
2. VICI Properties Inc. (NYSE:VICI)
On July 8, 2026, Morgan Stanley lowered the firm’s price target on VICI Properties Inc. (NYSE:VICI) to $31 from $38 and kept an Equal Weight rating on the shares.
On June 25, RBC Capital analyst Brad Heffern initiated coverage of VICI Properties with a Sector Perform rating and $29 price target. Heffern said low coverage on the company’s Caesars Regional lease makes a rent cut feel likely at some point. Heffern also said VICI’s top two tenants potentially going private reduces visibility, while RBC sees a fair valuation at current share levels.
Last month, Club Med and VICI Properties announced the acquisition and planned redevelopment of the iconic Carambola Beach Resort in the U.S. Virgin Islands, marking the return of Club Med to U.S. shores. The company said the future Club Med St. Croix will reinforce the brand’s leadership in the premium all-inclusive category while bringing renewed activity to the destination’s historic beachfront property.
VICI Properties Inc. (NYSE:VICI) is an S&P 500 real estate investment trust that owns gaming, hospitality, wellness, entertainment, and leisure destinations.
1. Netflix, Inc. (NASDAQ:NFLX)
On July 10, 2026, Variety’s Todd Spangler reported that popular film-review social network Letterboxd has been shopping itself to interested parties in recent months, citing an unconfirmed report from Puck. Netflix, Inc. (NASDAQ:NFLX) is in talks to acquire the company, while Sony Pictures (SONY), Paramount Skydance (PSKY), and private equity firm TPG are also reportedly looking at a deal for Letterboxd.
Also on July 10, The Wall Street Journal’s Jessica Toonkel and Ben Fritz reported that while Netflix customer defections remain at industry lows, subscriber engagement has been showing signs of decline, citing sources quoting attendees of the company’s annual business review this spring. In response, Netflix executives have recently discussed adding live channels that would continuously stream certain programs and have also explored bundling other subscription-based streaming services.
On July 9, Citi analyst Jason Bazinet lowered the firm’s price target on Netflix to $100 from $115 and kept a Buy rating on the shares. Bazinet said tepid viewership, an M&A overhang, the perception that Netflix lacks catalysts, and investor enthusiasm for semis have pressured Netflix’s share price and sentiment, though Citi remains “more upbeat.” Bazinet also said potential new tiers could help Netflix segment more effectively, support top-line growth, and reignite investor interest, while M&A could help fortify its intellectual property position.
Netflix, Inc. (NASDAQ:NFLX) provides entertainment services worldwide, including TV series, documentaries, feature films, games, and live programming across various genres and languages.
While we acknowledge the potential of NFLX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NFLX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Fastest Growing Asian Stocks to Buy Now and 12 High Quality Stocks to Buy for the Long Term.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
